Exploring Non-Dilutive Grant Funding for Clinical Trial Initiatives: Q&A with Mydecine CEO Josh Bartch
By John Jannarone Funding for therapeutic medicine can be controversial, especially in the case of psilocybin. To address recent investor questions, IPO Edge spoke Wednesday with Mydecine Innovations Group, […]